Lipitor vs Repatha
Side-by-side cost comparison based on Medicare Part D data
Lipitor
Atorvastatin
Manufactured by Pfizer
Repatha
Evolocumab
Manufactured by Amgen
Lipitor costs 98% less per claim than Repatha ($16.00 vs $757.00). A generic version of Lipitor is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Lipitor | Repatha |
|---|---|---|
| Avg Cost Per Claim | $16.00 | $757.00 |
| Total Medicare Spending | $456.0M | $2.6B |
| Total Beneficiaries | 4,120,000 | 398,000 |
| Total Claims | 28,960,000 | 3,420,000 |
| Annual Cost/Patient | $111.00 | $6,505.00 |
| Year-over-Year Change | -56.3% | +24.6% |
| Generic Available | Yes | No |
| Patent Expiration | Nov 30, 2011 | Aug 27, 2029 |
| Manufacturer | Pfizer | Amgen |
| Condition | High Cholesterol | High Cholesterol |
| Generic Name | Atorvastatin | Evolocumab |
Lipitor vs Repatha: What the Data Shows
Lipitor (Atorvastatin) and Repatha (Evolocumab) are both used to treat high cholesterol. Based on Medicare Part D data, Lipitor costs $16.00 per claim, which is 98% less than Repatha at $757.00 per claim.
Medicare spent $456.0M on Lipitor and $2.6B on Repatha. In terms of patient reach, Lipitor serves more beneficiaries (4,120,000 vs 398,000).
Year-over-year spending changed -56.3% for Lipitor and +24.6% for Repatha. Repatha saw significant spending growth, suggesting increased utilization or price increases.
Lipitor has a generic available, while Repatha remains brand-only until its patent expires Aug 27, 2029.
Frequently Asked Questions
Lipitor is cheaper at $16.00 per claim, compared to $757.00 for Repatha. That makes Lipitor about 98% less expensive per claim based on Medicare Part D data.
Yes, both Lipitor and Repatha are used to treat high cholesterol. Your doctor can help determine which medication is more appropriate for your specific situation.
Lipitor has a generic version (Atorvastatin) available, which is typically much cheaper. Repatha is currently brand-only, with patent expiring Aug 27, 2029.
Medicare Part D spent $456.0M on Lipitor covering 4,120,000 beneficiaries, and $2.6B on Repatha covering 398,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.